Corcept Therapeutics Stock: A Deep Dive Into Analyst Perspectives (4 Ratings)
Portfolio Pulse from Benzinga Insights
Corcept Therapeutics (NASDAQ:CORT) has received 4 bullish analyst ratings over the past three months. Analysts have set a 12-month price target range of $38.00 to $44.00, with an average target of $40.5. The company's recent financial performance includes a 38.95% revenue growth rate and an 18.74% net margin, although its ROE is below industry averages.
May 29, 2024 | 1:00 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Corcept Therapeutics has received 4 bullish ratings from analysts in the past three months, with a 12-month price target range of $38.00 to $44.00. The company has shown strong financial performance, including a 38.95% revenue growth rate and an 18.74% net margin.
The unanimous bullish ratings from analysts and the positive financial metrics such as high revenue growth and net margin suggest a favorable short-term outlook for Corcept Therapeutics. The price targets indicate confidence in the stock's potential to appreciate.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100